

Vaccine Fact Sheet: Zoster/Shingles

Topic	SHINGRIX
Manufacturer	GlaxoSmithKline (GSK) Prescribing Info (FDA)
Protects Against	Herpes Zoster (shingles)
Approved Ages	18 years & older
Funding Source	VFA LHD 317
Routine Schedule	2-dose series: 2–6 months apart for 50 years & older, or 19 years & older with weakened immune system
Minimum Intervals	4 weeks
Administration	Intramuscular (IM) injection
Packaging	Vaccine packaged as 1 dose (1 vial of lyophilized antigen and 1 vial of liquid adjuvant component) or 10 doses (10 vials of lyophilized antigen and 10 vials of liquid adjuvant component)
Storage	Refrigerate between 36° and 46° (2° and 8° C). Protect vaccine from light. Do not freeze. Discard if frozen.
Recommendations	AAFP Immunization Schedule (PDF) CDC's MMWR (2022) CDC's MMWR (2018)
Program Letter	VFA Clinical Letter (PDF)
Billing Codes	CPT code for vaccine: 90750 CPT code for administration: 90471 or 90742 ICD-10-CM code: Z23 Administration Modifier for Medicare: GY Coding for Vaccine Administration (PDF)
Comments	<ul style="list-style-type: none"> • Licensed in 2017 • Patients who have had shingles or previously received Zostavax are also recommended to be vaccinated with Shingrix • If administered SC, it is not necessary to repeat dose

Refer to [Vaccine Fact Sheets](https://EZIZ.org/Resources/VaccineFactSheets) (EZIZ.org/Resources/VaccineFactSheets).